Teva Pharmaceutical Industries Ltd. (TEVA) today announced positive top-line results from the GALA (Glatiramer Acetate Low-Frequency Administration) Phase III clinical trial assessing the efficacy, safety and tolerability of 40 mg/1 ml glatiramer acetate injection (GA) administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis(RRMS) patients. Study results showed that GA 40 mg/1 ml significantly reduced disease activity, while maintaining a favorable safety and tolerability profile.
READ MORE
READ MORE
..
Please note that all comments are moderated.
So that you can be kept up to date with MS news
Click here to: REGISTER – for our weekly e-Newsletter
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
